Daily treatment with mavorixafor improved outcomes among patients with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, in the 4WHIM phase 3 clinical trial, according to the drug’s developer, X4 Pharmaceuticals.WHIM syndrome is a rare, combined immunodeficiency disease caused by reduced mobilization and trafficking of white blood cells from the bone marrow due